Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta to Expand Sales Territories, Rebrands Lead Cancer Diagnostic


Rosetta Genomics this week announced that it plans to expand its US commercial operations from five sales territories to 12 next month.

The company also said that it has rebranded its flagship microRNA-based diagnostic MiRview Mets2, which is designed to identify the source of cancers of unknown primary origin, as the Rosetta Cancer Origin test.